Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924171 | 0.86 | HDAC6 (0.35) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL342693 | 0.82 | AAK1 (0.33) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL342692 | 0.82 | AAK1 (0.33) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL357909 | 0.82 | AAK1 (0.33) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL21294449 | 0.82 | AAK1 (0.35) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL21294450 | 0.82 | AAK1 (0.35) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL18787667 | 0.82 | CYP2D6 (0.36) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL18787668 | 0.82 | CYP2D6 (0.36) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL21431256 | 0.81 | NFKB1 (0.39) | AAK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL6248078 | 0.81 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | AAK1 2653/4885HDAC6 747/4885HDAC1 548/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | AAK1 2653/4885HDAC6 747/4885HDAC1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.